Lungpacer Medical

Lungpacer Medical publicly announces its PMA submission for the AeroPace System, an interventional therapy designed to improve diaphragm strength and help people with ventilator dependence regain independent breathing faster. Click here to view the press release in its entirety: https://lnkd.in/gX55u7A5

Premarket Approval for Lungpacer Medical's AeroPace System! In memory of my son, Cameron, who endured the challenges of mechanical ventilation, we extend gratitude to our amazing employees for their steadfast commitment to our mission, to the dedicated physicians who conducted our three clinical trials and to the brave patients who participated in them such that their efforts will help patients wean faster. Thank you!

Lungpacer Medical, a neurostimulation company dedicated to developing innovative interventional therapies to free patients from mechanical ventilation (MV) and improve diaphragm, lung, heart, and brain health, today announced premarket approval from the U.S. Food and Drug Administration (FDA) for the Company’s flagship AeroPace® System.   AeroPace is the world’s first approved therapy that stimulates the nerves that activate the diaphragm to rebuild strength and reduce time on mechanical ventilation. Visit us online at Lungpacer.com for details.

Lungpacer Medical is pleased to announce the publication of data indicating that Lungpacer AeroNova Therapy restores brain activity, connectivity, and synchronization in sedated mechanically-ventilated patients with acute respiratory distress syndrome (ARDS). "Restoring brain connectivity by phrenic nerve stimulation in sedated and mechanically ventilated patients" was published this week in Communications Medicine Nov 2024.

We're #hiring a new Quality Assurance Associate in Exton, Pennsylvania. Apply today or share this post with your network.

We are pleased to share that Idunn Morris, MD presented results from Lungpacer Medical’s STIMULUS I Clinical Study at the European Society of Intensive Care Medicine - ESICM LIVES 2024 Congress in Barcelona, Spain. The research, entitled "Continuous on‑demand phrenic nerve stimulation to maintain diaphragm activity during mechanical ventilation for acute respiratory failure: The STIMULUS clinical trial", was selected as a top 10 conference abstract out of over 1000 submissions. Congratulations to Drs. Morris, Dres, Brochard, Ferguson, Goligher and the other authors. Visit us online at Lungpacer.com/patents for details.

Lungpacer Medical is pleased to share this recent publication, which reinforces the need for new therapies to improve outcomes for ventilated critical care patients: "Lung and Diaphragm Protection During Mechanical Ventilation in Patients with Acute Respiratory Distress Syndrome," by Andrea Castellvi-Font, Ewan Goligher, Jose Dianti, published in the Clinics in Chest Medicine Journal, October 2024. As the authors noted, "Although lifesaving, positive pressure mechanical ventilation can potentially injure the lungs and diaphragm, further worsening patient outcomes."

We are pleased to highlight a recent Lungpacer publication, “Transvenous Phrenic Nerve Stimulation Reduces Diaphragm Injury During Controlled Mechanical Ventilation In A Preclinical Model of ARDS.” Congratulations to Elizabeth Rohrs, Karl Fernandez, Thiago Bassi, Michelle Nicholas, Jessica Wittmann, Marlena Ornowska, Matt Gani, Isabella Dakin, and Steven Reynolds. 

In a new study, using a ventilator-on-a-chip model developed at The Ohio State University, for the first time scientists were able to directly compare the different kinds of injury that mechanical ventilation causes to cells in the lungs. Experiments showed that both overinflation with a high volume of air, as well as the cyclic collapse and reopening of air sacs both led to lung injury. Our mission at Lungpacer Medical is to mitigate both of these types of injury as evidenced by Elizabeth Rohrs, Thiago Bassi, et al, Diaphragm neurostimulation during mechanical ventilation reduces atelectasis and transpulmonary plateau pressure, preserving lung homogeneity and preserving lung homogeneity and PaO2/FIO2. J Appl Physiol, 2021. Our team is dedicated to advancing this innovative therapy so that clinicians can improve outcomes for their patients in the future.